P1RG34 Stock Overview
Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Perrigo Company plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$148.27 |
| 52 Week High | US$154.05 |
| 52 Week Low | US$130.53 |
| Beta | 0.52 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -26.85% |
| 5 Year Change | n/a |
| Change since IPO | -40.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| P1RG34 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | 0% | -3.9% | -2.9% |
| 1Y | n/a | -27.3% | -9.2% |
Return vs Industry: Insufficient data to determine how P1RG34 performed against the BR Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how P1RG34 performed against the BR Market.
Price Volatility
| P1RG34 volatility | |
|---|---|
| P1RG34 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in BR Market | 9.1% |
| 10% least volatile stocks in BR Market | 2.7% |
Stable Share Price: P1RG34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine P1RG34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1887 | 9,140 | Patrick Lockwood-Taylor | www.perrigo.com |
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Perrigo Company plc Fundamentals Summary
| P1RG34 fundamental statistics | |
|---|---|
| Market cap | R$22.01b |
| Earnings (TTM) | -R$897.34m |
| Revenue (TTM) | R$26.83b |
0.8x
P/S Ratio-24.5x
P/E RatioIs P1RG34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P1RG34 income statement (TTM) | |
|---|---|
| Revenue | US$4.39b |
| Cost of Revenue | US$2.81b |
| Gross Profit | US$1.58b |
| Other Expenses | US$1.73b |
| Earnings | -US$146.90m |
Last Reported Earnings
Sep 28, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 36.07% |
| Net Profit Margin | -3.34% |
| Debt/Equity Ratio | 104.8% |
How did P1RG34 perform over the long term?
See historical performance and comparisonDividends
4.2%
Current Dividend Yield-103%
Payout RatioDoes P1RG34 pay a reliable dividends?
See P1RG34 dividend history and benchmarks| Perrigo dividend dates | |
|---|---|
| Ex Dividend Date | Nov 28 2024 |
| Dividend Pay Date | Dec 23 2024 |
| Days until Ex dividend | 21 days |
| Days until Dividend pay date | 4 days |
Does P1RG34 pay a reliable dividends?
See P1RG34 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 21:16 |
| End of Day Share Price | 2024/10/21 00:00 |
| Earnings | 2024/09/28 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Perrigo Company plc is covered by 38 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Douglas Tsao | Barclays |